CME Group’s stock (NYSE: CME) has gained 21% YTD, as compared to the 15% rise in the S&P500 over the same period. Further, at its current price of $203 per share, it is trading 6% below its fair value of $215 – Trefis’ estimate for CME Group’s valuation.
Interestingly, CME Group
CME
The company surpassed the street estimates in the second quarter of 2023, with total revenues increasing by 10% y-o-y to $1.36 billion. It was primarily driven by a 9% growth in clearing & transaction fees, followed by an 8% rise in market data & information services revenues. Notably, the clearing & transaction fees benefited from a higher average rate per contract, partially offset by a marginal drop in the aggregate average daily volume. On the cost front, the operating margin improved from 60.6% to 61.7%. Further, the non-operating income increased 52% to $177.8 million. Overall, it resulted in a net income of $777.6 million – up 17% y-o-y.
The company’s top line grew 8% y-o-y to $2.8 billion in the first half of FY 2023, driven by a 7% improvement in clearing & transaction fees and an 8% rise in market data & information services revenues. The growth in clearing & transaction fees was because of higher aggregate ADV (up 2% y-o-y) and growth in average rate per contract. In addition, the non-operating income rose from $174.2 million to $421 million over the same period. It led to a 21% y-o-y increase in the net income to $1.66 billion.
Moving forward, we expect the same trend to continue in the subsequent quarters. Altogether, CME Group revenues are forecast to touch $5.44 billion in FY2023. Additionally, CME’s adjusted net income is likely to be around $3.24 billion in the year. This coupled with an annual EPS of $9.03 and a P/E multiple of just below 24x will lead to a valuation of $215.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
Read the full article here